497 related articles for article (PubMed ID: 18303987)
21. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
24. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; Goldman JM; Apperley JF; Kaeda J
Leukemia; 2006 Apr; 20(4):658-63. PubMed ID: 16467863
[TBL] [Abstract][Full Text] [Related]
25. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
26. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
27. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
28. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
31. Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Sakamoto Y; Mariya Y; Oshikiri T; Sasaki S; Segawa M; Teshiromori R; Ogura K; Akagi T; Kaimori M; Kubo K
Acta Med Okayama; 2011 Oct; 65(5):335-42. PubMed ID: 22037271
[TBL] [Abstract][Full Text] [Related]
32. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
[TBL] [Abstract][Full Text] [Related]
33. Detection of BCR-ABL mutations and resistance to imatinib mesylate.
Branford S; Hughes T
Methods Mol Med; 2006; 125():93-106. PubMed ID: 16502579
[TBL] [Abstract][Full Text] [Related]
34. Monitoring disease response to tyrosine kinase inhibitor therapy in CML.
Hughes TP; Branford S
Hematology Am Soc Hematol Educ Program; 2009; ():477-87. PubMed ID: 20008233
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
36. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Lange T; Park B; Willis SG; Deininger MW
Cell Cycle; 2005 Dec; 4(12):1761-6. PubMed ID: 16319529
[TBL] [Abstract][Full Text] [Related]
37. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
Liu J; Zhao XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
[TBL] [Abstract][Full Text] [Related]
38. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
39. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
40. Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Strhakova L; Bujalkova MG; Hojsikova I; Lukackova R; Behulova R; Mistrik M; Repiska V
Neoplasma; 2011; 58(6):548-53. PubMed ID: 21895409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]